Barclays PLC Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Barclays PLC grew its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 285.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,312 shares of the company’s stock after acquiring an additional 73,542 shares during the quarter. Barclays PLC’s holdings in Aquestive Therapeutics were worth $495,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Wellington Management Group LLP purchased a new stake in Aquestive Therapeutics in the third quarter valued at approximately $922,000. State Street Corp lifted its position in shares of Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at approximately $995,000. MetLife Investment Management LLC boosted its holdings in shares of Aquestive Therapeutics by 86.3% in the 3rd quarter. MetLife Investment Management LLC now owns 36,096 shares of the company’s stock valued at $180,000 after buying an additional 16,716 shares during the period. Finally, BNP Paribas Financial Markets raised its position in shares of Aquestive Therapeutics by 252.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 3.1 %

Shares of AQST stock opened at $3.67 on Friday. The company’s fifty day simple moving average is $4.45 and its 200-day simple moving average is $4.11. The firm has a market cap of $334.62 million, a PE ratio of -8.16 and a beta of 2.63. Aquestive Therapeutics, Inc. has a 12 month low of $1.98 and a 12 month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. On average, equities analysts predict that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AQST has been the topic of several analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. Finally, Leerink Partners boosted their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.